Create Account | Sign In: Author or Forum

News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
Category: Family Medicine | Internal Medicine | Nursing | Pharmacy | Anesthesiology & Pain | Institutional

Back to Journal Articles

FDA Panels Vote Against Plan to Reduce Opioid Abuse

Last Updated: July 26, 2010.


Key issue cited by an FDA official was lack of mandatory training for prescribing doctors

Share |

Comments: (0)



On July 23, two U.S. Food and Drug Administration advisory panels voted against the FDA's plan for reducing abuse of long-acting and extended-release opioid drugs.

MONDAY, July 26 (HealthDay News) -- On July 23, two U.S. Food and Drug Administration advisory panels voted against the FDA's plan for reducing abuse of long-acting and extended-release opioid drugs.

In February, the FDA issued a Risk Evaluation and Mitigation Strategy (REMS) for all extended-release and long-acting opioid drugs in an attempt to rein in the growing misuse and abuse of the drugs by educating physicians and patients about associated risks. Extended-release and long-acting opioids pose an increased risk of serious adverse events compared with shorter-acting formulations due to their formulations and chemical properties.

However, during the joint meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management advisory committees, committee members voted 25 to 10 against the FDA's proposal. John Jenkins, M.D., director of the Office of New Drugs in the FDA's Center for Drug Evaluation and Research, said at a news conference that the members who voted no believe a REMS is needed but that the FDA's proposal did not go far enough. Specifically, he said those who voted no wanted the training for prescribing physicians to be mandatory, not voluntary. He noted that the magnitude of such a training program would be extremely large.

"There are concerns about the burden that would place on the health care system. Because of the size of the program, there were concerns that some prescribers might choose to opt out of the program, and that might impact on patients' access to care for relief of their pain," Jenkins added.

More Information

Copyright © 2010 HealthDay. All rights reserved.

Previous: Medical Device-Related Injuries High in Pediatric Population Next: NCCN and Proventys Collaborate to Provide Point of Care Access to Guidelines

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion:





Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)



Useful Sites
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2015
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.